Purpose: To re-examine drug-resistant epilepsy cases using the revised 2011 ILAE classification of focal cortical dysplasia (FCD). Methods: Patients with drug-resistant epilepsy who have undergone epilepsy surgery in West China Hospital between July 2012 and Jun 2014 were included. Clinical histories, pathological diagnoses, and surgical outcomes were reviewed. A questionnaire was developed to investigate the clinical practice of the new classification. A short-term training program on FCD was carried out to improve pathological diagnosis accuracy. Results: 260 consecutive cases (177 male and 83 female) were included. Pathological diagnosis was changed in 70 cases (26.9%) after re-examination. The five most common pathological types were hippocampal sclerosis (19.2%, 50/260), brain tumors (17.7%, 46/260), vascular malformations (16.2%, 42/ 260), glial scars (11.2%, 29/260) and FCD (10.0%, 26/260). The most common subtype of isolated FCD was FCD IIb (53.8%, 14/26), followed by FCD IIa (42.3%, 11/26) and FCD Ib (3.8%, 1/26). In addition, forty-five cases were diagnosed as associated FCD type III (17.3%, 45/260). Half of patients with FCD achieved Engel class I at two-year follow-up. Questionnaire investigation suggested most participant pathologists lack sufficient knowledge on the new classification. The diagnostic sensitivity for different FCD subtypes was significantly improved by two to six folds after short-term training. Conclusions: FCD is an important etiology of drug-resistant epilepsy in western China. It is essential to provide continuing trainings to improve diagnostic precision of FCD in developing countries.
Introduction
Focal cortical dysplasia (FCD) is frequently associated with drug-resistant epilepsy in both children and adults [1] . It is reported with higher recurrence rate after epilepsy surgeries compared to other etiologies such as neoplasm and vascular malformations, which raises the need for adopted surgical strategies for FCD [2] [3] [4] [5] . In addition, the clinical manifestation, post-surgical short-term and long-term outcome of patients varies between different FCD subtypes [6] [7] [8] . Therefore, it is of great importance to report a reliable histopathological diagnosis in clinical practice and patient management.
With the advancement of neuroimaging technologies, presurgical assessment of focal epilepsies has been considerably improved. However, currently reported neuroimaging signal alterations are not fully reliable to establish a final diagnosis of FCD [7] . Definite diagnosis of FCD still depends on pathological examination of surgical specimens. In 2011, the International League Against Epilepsy (ILAE) proposed a novel three-tiered classification system for FCD that specified a novel, associated form (FCD III) to be distinguish from isolated forms (FCD I and II) [9] . Although the new classification has been issued for a few years, clinical practice of this classification and detection rates of FCDs in developing countries have never been assessed. Aims of this project were: 1) To investigate the incidence of different FCD subtypes in western China; 2) To explore whether re-examination of drug-resistant case using the new classification of FCDs affect the clinical summary and prognosis of our patients; 3) To estimate the occurrence and potential cause of misdiagnosis of FCDs in our institution; 4) To evaluate the efficacy of short-term training program on pathological diagnosis of FCDs.
Materials and methods

Patients and clinical data
A retrospective study was conducted in West China Hospital, Sichuan University, a tertiary hospital mainly for adults in western China. The study was approved by the Ethics Committee of West China Hospital, Sichuan University. Consecutive patients who had undergone epilepsy surgery for drug-resistant epilepsy from July 2012 to June 2014 were included. Clinical data including age, sex, age at seizure onset, epilepsy duration and seizure type were reviewed from electronic medical charts. Epileptic seizures were classified as focal or generalized seizures, according to the 2010 ILAE guidelines [10] . All patients were evaluated by pre-surgical evaluation including video electroencephalography (VEEG), brain magnetic resonance imaging (MRI) and reviewed by experienced experts in our institution. Epileptiform discharges revealed by VEEG were classified into focal, unilateral, bilateral, generalized, or alternating bilateral.
Pathological re-examination procedures
All surgical specimens were fixed in a 4% buffered formaldehyde solution, dehydrated and embedded into paraffin. Paraffin sections were serially cut into 4 mm and stained with haematoxylin and eosin (H&E). Primary antibodies were applied as following: antibodies against neuronal nuclear antigen (NeuN; 1:2000, Abcam, USA), neurofilament protein (NF, 1:200, Chemicon, USA), glial fibrillary acidic protein (GFAP; 1:500, Abcam, USA), nestin (1:100, Thermo Scientific Pierce Product, USA), synaptophysin (SYP, 1:400, Abcam, USA), microtubule-associated protein-2 (MAP-2; 1:300, Abcam, USA), non-phosphorylated neurofilament H monoclonal antibody (SMI-32, 1:2500, Biolegend, USA), vimentin (1:100, Abcam, USA), CD34 (1:100, Thermo Scientific Pierce Product, USA), Ki-67 (1:200, Abcam, USA), Epithelial membrane antigen (EMA, 1:100, Dako, Denmark), Olig2 (1:500, Millipore, USA), Phosphatase and tensin homolog (PTEN, 1:50; Abcam, USA), O-6-methylguanine-DNA methyltransferase (MGMT, 1:500; Thermo Scientific Pierce Product, USA), S-100 (1:500; Sigma-Aldrich, USA), matrix metalloproteinase 9 (MMP-9, 1:50; Santa Cruz Biotechnology, USA). Appropriate positive and negative controls were always performed.
The slides were independently re-examined by two neuropathologists, experienced in FCD diagnosis and not involved in the initial examination. In cases of disagreement, specimens were jointly reviewed at a multihead microscope and referred to a third expert. Special stains and immunohistochemistry were processed for selected sections according to the 2011 ILAE classification system [9] . Tumors were classified according to the latest World Health Organization classification of tumors of the central nervous system 2016 [11] . HS was diagnosed in the presence of astrogliosis and segmental pyramidal cell loss in CA1, CA3 or CA4 sectors of Ammon's horn [12] . Dual pathology refers to HS with a second principal lesion [9] .
Follow-up
All patients with histopathologically proved FCD were followed-up for two years by outpatient visit or telephone interviews. According to Engel classification, seizure outcomes were classified into class I, completely seizure free for at least 2 years, auras only, or convulsions with drug withdrawal only; class II, rare seizure ( 2 seizures per year); class III, worthwhile improvement; and class IV, no significant improvement or worse [13] .
Questionnaire investigation and selection of participant pathologists
We developed a questionnaire containing eight questions ( Supplementary Fig. 1 ) and randomly distributed the questionnaire to 15 staff pathologists in the Department of Pathology in our institution. All participant pathologists have worked for at least two years. The subjects' anonymity was guaranteed.
FCD diagnosis training program
A three-day interactive training program was developed to improve awareness of FCD as a common etiology of drug-resistant focal epilepsy. The program consisted of three parts. Firstly, neuropathology experts performed a series of educational courses on the differential diagnosis of epilepsy-associated brain lesions, including introduction of ILAE classification of FCD. Secondly, a series of 22 surgical specimens containing 100 stained glass slides were reviewed under microscopes and discussed across class. It covers a broad spectrum of epilepsy associated brain lesions, including hippocampal sclerosis, vascular malformations, epilepsy associated brain tumors and FCD as well as other malformations of cortical development. Thirdly, difficult cases were discussed together using a multihead microscope to further familiarize pathologists with diagnosis and recommended special stains for FCD (see above). After the training program, 5 staff pathologists were asked to review additional 20 cases with different pathologies, including FCD, HS, tumor and non-specific changes to assess improvement of diagnostic accuracy, sensitivity and specificity after the training program.
Statistic analysis
The data were analyzed using SPSS 19.0 (SPSS Inc., Chicago, USA). Changes of diagnostic accuracy, specificity and sensitivity were analyzed by related-sample Wilcoxon signed rank test.
Questionnaire data were summarized and deductions were made. P < 0.05 was considered as statistically significant.
Results
A total of 260 consecutive drug-resistant epilepsy cases (male: female = 177: 83) were included ( Table 1 ). The mean age at surgery was 25.1 years, and mean disease duration was 7.0 years. There were 154 (59.2%) temporal lobe epilepsy cases and 106 (40.8%) extra-temporal lobe cases.
Clinical characteristic of FCD
A total of 26 isolated FCDs were identified after re-examination ( Table 2 Most (84.6%, 60/71) epileptic FCD cases in our cohort showed abnormalities on MRI. The MRI result of patient with FCD I was negative in our study. Abnormal gyration, blurred gray-white matter transition and increased signal intensity were primary MRI findings of FCD II (Supplementary Fig. 2 ). Typical imaging features of FCD III included atrophy or/and increased flair signaling of 
Comparison of pathology diagnosis using new ILAE's classification
After re-examination, diagnoses were changed in 70 cases (26.9%; Fig. 2 ). The five most common pathologies included HS (19.2%, 50/260), tumors (17.7%, 46/260), vascular malformations (16.2%, 42/260), glial scars (11.2%, 29/260) and FCD (10.0%, 26/260). During the initial pathologic examination, 31 cases were classified as "non-specific changes". Microscopic descriptions included "in accordance with epileptic changes" and "neuronal degeneration with gliocyte proliferation" (Fig. 1) . The rate of non-specific histopathological changes declined to 3.1% after re-examination.
At initial examination, 14 isolated FCD and 45 associated FCD cases were undiagnosed or misdiagnosed in our institution ( Fig. 2A) . Only 4 FCD IIa and 8 FCD IIb were correctly classified. Associated FCD III was the most frequently misdiagnosed FCD subtype (Fig. 2B) , initially diagnosed as HS, tumor, vascular malformation, inflammation or scar lesion alone. One case of FCD Ib, 7 cases of FCD IIa and 6 cases of FCD IIb cases were misdiagnosed as mild malformation of cortical development.
Application of special stains
Special stains for pathological diagnosis were applied in 85 (85/ 260, 32.7%) cases while all remaining specimens were diagnosed only by H&E at initial examination ( Supplementary Fig. 3 ). Special stains were frequently used in epilepsy-associated tumor (97.8%) and dual pathologies (71.4%), including antibodies directed against GFAP, Olig2, NeuN, NF, IDH1, Syn, CD34, MGMT, PTEN, P53 and Ki-67. Only 26.9% (7/26) of FCD sections were immunohistochemically reviewed, most of which were FCD IIIb. No application of MAP-2, vimentin and SMI-32 antibodies on FCD cases was found in our series at initial examination. Classic examples of histopathological findings of FCD and other typical lesions were shown in Fig. 3. 
Questionnaire results
Two thirds of participant pathologists in our questionnaire examined epilepsy surgery specimens during their daily work ( Supplementary Fig. 1A ). Most participants were familiar/very familiar with the definition of focal cortical dysplasia (73.3%; Supplementary Fig. 1B) . However, less than 35% of participants considered FCD as common pathology for drug-resistant epilepsy ( Supplementary Fig. 1C ). Nearly half of them never made the diagnosis of FCD in epilepsy surgery (Supplementary Fig. 1D ). More than 60% of participants lack sufficient knowledge about the 2011 ILEA classification of FCD, suggested special stains and diagnostic procedures ( Supplementary Fig. 1E and 1F) . Nearly 90% of all participants never or occasionally attended training courses focused on FCD diagnosis before (Supplementary Fig. 1G ).
Short-term training program
After a short-term histopathology training program assessing a set of 20 surgical cases, diagnostic accuracy improved for all three FCD subtypes, although statistic significance was not reached (see Table 3 ). The diagnostic sensitivities for FCD type I, II and III were 13%, 35% and 20% before training, and significantly improved afterwards to reach 73%, 80% and 60% respectively (p = 0.043 for FCDI, 0.034 for FCDII and 0.043 for FCDIII) while specificity remained unchanged.
Discussion
We retrospectively reviewed brain specimens collected from epilepsy surgery in a two-year period and found that the five leading pathologies of drug-resistant epilepsy were HS, tumor, vascular malformation, scar lesion and FCD. Besides, FCD II was the most common FCD subtype while FCD I was merely encountered. The overall percentage of FCD in our study was lower than that reported by Piao et al. [14] , who reviewed 435 drug-resistant epilepsy cases and found the three most common causes were FCD (52.9%), scar lesion (22.8%) and tumor (11.7%) [14] . Several previous studies also showed FCD II (40%) as the most common subtype, but higher incidence of FCD I was reported [15] [16] [17] . The discrepancy might due to different classification criteria and regional difference, as well as low surgical rate of patients with FCD I due to frequent negative findings on MRI. As a tertiary hospital mainly for adult patients, low recruitment of FCD cases with younger age in the present study might also contribute to lower inclusion of FCD I cases as well. Focal seizure with VEEG discharges originating from unilateral region was the most common seizure type presented in each FCD subtype, which could be attributed to "focal origin character" of FCD [4] . In addition, patients diagnosed of tumor without associated FCD had shorter seizure duration than tumor with FCD IIIb.
Most epileptic FCD cases (84.6%) in our cohort showed abnormalities on MRI, and transmantle signs were commonly found in FCD IIb. Although only one case of FCD I was identified in our study, the MRI finding of FCD I was usually negative as suggested by previous literatures [16, 18, 19] . Two cases showed abnormal image result after application of thinner layer scan for flair image (3T, 3-5 mm). It suggests that transmantle sign, blurred grey-white matter of FCD could be found by advanced neuroimaging techniques, such as fMRI, 7 tesla MRI, PET/CT in association with VEEG, cortex EEG monitoring mentioned in previous studies [20, 21] .
In our study, half of the patients achieved Engel class I at twoyear follow-up. More patient with HS achieved seizure-free than those diagnosed of HS with FCD IIIa. Poor prognosis for HS with FCD IIIa was also demonstrated in previous study [17] . As defined by the classification, patient with FCD IIIa have more structural involvement other than hippocampus. Although we lacked the detailed information about surgical resection extension, it was assumed the unsatisfactory outcome might partially due to insufficient resection of surrounding lesions. In this series, patients with tumor had shorter disease duration before surgery than patients diagnosed of tumor with FCD IIIb, which may attribute to different WHO grade classification. Low-grade tumors with slow development are more common in FCD IIIb. Due to relatively small sample size and short follow-up in our study, further investigation on this subject is needed to confirm our results.
The pathological diagnostic gap in our institution is distinct. Many FCD cases was undiagnosed or misdiagnosed at the initial pathologic examination. The most frequently un-diagnosed subtype was associated FCD III, which was often diagnosed as the tumor, vascular malformation or necrosis alone. This might due to the ignorance of the surrounding architectural changes and the new definition of FCD III was not applied in the past.
Special stains could improve pathological diagnostic precision [22] . MAP2, SMI-32, vimentin and NeuN, were applied for differential pathologic diagnosis at the re-examination process. Immunohistochemistry revealed that NeuN was an excellent marker of neuronal cells, including giant, immature and dysmorphic neurons, and normal pyramidal cells. It was useful for revealing cortical lamination and organization of FCD I, as well as for detecting cytoarchitectural disturbances such as dysmorphic neurons. MAP2 could also strongly detect immature neurons. Accumulation of SMI-32 was frequently found in dysmorphic neurons, helpful for differentiating FCD II. Bolloon cells were positively stained with vimentin, indicative for FCD IIb. At the initial diagnosis, special stains were commonly used when considering neoplastic changes whilst only H&E stains were applied for most other non-tumoral cases. It may be the main cause for lower diagnostic precision in our institution. After application of specific stains and immunohistochemistry procedure during reexamination, more cases were correctly diagnosed.
The questionnaire investigation showed pathologists not specialized on neuropathology made pathologic examination for epileptic surgery specimens during their daily work. FCD has been studied for a long period of time in developed countries, but it has not gained enough attention in developing areas. According to our investigation, the primary problem was lack of educational courses and training programs focused on FCD, which lead to three evident consequences: 1) unawareness of the high incidence of FCD as the cause of drug-resistant epilepsy; 2) unfamiliar with the pathological characteristics and new classification of FCD; 3) low application rate of special stains for diagnosis of FCD. All these factors severely hampered differentiation diagnosis of FCD.
The pathological diagnostic gap of FCD in developing areas raises the urgent requirement for improvement. After performing a short-term training program, we found the diagnostic sensitivity of FCD II and III were significantly improved. The diagnostic accuracy for all three FCD subtypes was also improved. The results reflected that short-term training might have obvious effect on diagnostic results.
Conclusion
In conclusion, FCD is an important etiological factor of drugresistant epilepsy in western China. The new classification of FCD may be helpful for pre-estimating surgical outcome. It is essential to provide continuing training to improve diagnostic precision of FCD.
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